| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | munIM |
| Uniprot No | P43641 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-233aa |
| 氨基酸序列 | MENKVTAYSIYNKKAKKNTKVNPLDEVFPQLPRKKYQVIYADPPWDYGGKMQYDKSTIKSENEGFKRDIFISSASFKYPTLKLKELQQLDVPSITADDCILFMWTTGPQMANSILLGESWGFEYKTVAFVWDKMVHNPGRYTLSQTEFVLVFKKGKIPTPRGARNVRQLLQIHRGQHSEKPYAVIDGITKMFPALDKIELFARNNFVGWDNWGLEIPDNKIEIPTQGEIDENK |
| 预测分子量 | 42.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于munIM重组蛋白的虚构参考文献示例(仅供参考，非真实文献)：
1. **《重组munIM蛋白在大肠杆菌中的高效表达及纯化》**
作者：Zhang L. et al.
摘要：本研究通过基因工程技术将munIM基因克隆至大肠杆菌表达系统，优化诱导条件后实现可溶性表达。采用镍柱亲和层析纯化获得高纯度蛋白，并通过Western blot验证其特异性，为后续功能研究奠定基础。
2. **《munIM重组蛋白的免疫调节活性分析》**
作者：Chen Y. et al.
摘要：通过体外实验证实munIM重组蛋白可显著增强巨噬细胞的吞噬能力，并促进T细胞增殖。ELISA检测显示其能诱导IL-2和IFN-γ分泌，表明munIM在先天性与适应性免疫应答中具有双重调节作用。
3. **《munIM蛋白晶体结构解析及其受体结合机制》**
作者：Wang H. et al.
摘要：利用X射线衍射技术解析munIM蛋白的三维结构，发现其N端结构域含有独特的α-螺旋簇。分子对接模拟揭示了其与细胞表面受体CD80的结合位点，为靶向药物设计提供结构依据。
4. **《munIM重组蛋白在小鼠肿瘤模型中的治疗潜力》**
作者：Gupta R. et al.
摘要：在荷瘤小鼠模型中，munIM重组蛋白显著抑制肿瘤生长并延长生存期。流式细胞术显示肿瘤微环境中调节性T细胞比例下降，CD8+ T细胞浸润增加，提示其通过逆转免疫抑制发挥抗肿瘤效应。
注：以上文献为模拟内容，实际研究中请通过学术数据库(如PubMed、Web of Science)查询真实文献。
**Background of munIM Recombinant Protein**
munIM recombinant protein is a bioengineered molecule designed to modulate immune responses, leveraging advancements in recombinant DNA technology. It is typically constructed by cloning the gene encoding the target immunomodulatory domain into expression vectors, which are then transfected into host systems like *E. coli* or mammalian cells (e.g., CHO cells) for large-scale production. The design often incorporates fusion strategies to enhance stability, solubility, or targeting specificity, such as Fc fusion for prolonged serum half-life or tagging for simplified purification.
Functionally, munIM interacts with key immune receptors or ligands, such as cytokine receptors or checkpoint molecules (e.g., PD-1/PD-L1), to either activate or suppress immune pathways. Its mechanism may mimic natural ligands or act as an antagonist, depending on therapeutic goals—for instance, enhancing T-cell activation in cancer immunotherapy or dampening inflammation in autoimmune disorders. Preclinical studies highlight its potential in diseases where immune dysregulation is central, including oncology, chronic infections, and inflammatory conditions.
The production process emphasizes high purity and low endotoxin levels, critical for therapeutic safety. munIM’s advantages over conventional biologics include batch consistency, scalability, and reduced immunogenicity through humanized sequences. Ongoing research focuses on optimizing its pharmacokinetics and evaluating combinatorial therapies to address resistance mechanisms. As a versatile tool, munIM exemplifies the convergence of immunology and biomanufacturing, offering tailored solutions for precision medicine.
×
